Alkem Laboratories Peer Comparison

NSE: ALKEM | BSE: 539523

₹5,297.00

₹107.00 (2.06%)

As on 06-Nov-2026IST

Market cap

₹62,907 Cr

Revenue (TTM)

₹15,081 Cr

P/E Ratio

29.2

P/B Ratio

4.4

Div. Yield

1 %

Edit

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Market cap (₹ Cr)	62,907	1,19,481	1,14,073	1,04,628	1,03,039
Revenue (₹ Cr)	15,081	30,378	33,097	15,379	36,913
Net Profit (₹ Cr)	2,206.30	4,159.00	2,759.70	2,249.69	3,993.05
Net Margin (%)	14.07	13.20	8.03	14.32	10.61
RoE (%)	16.76	16.61	7.30	13.86	10.51
Price to Earnings	29.16	28.58	40.74	46.65	25.82
Price-To-Book	4.40	4.30	2.94	5.95	2.62

Income Statement (₹ Cr)

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Operating Revenue	15,081.28	30,378.10	33,097.40	15,378.58	36,912.88
Total Income	15,680.89	31,504.60	34,352.50	15,705.47	37,650.01
Total Expenditure	12,049.07	22,828.30	28,236.90	11,301.83	29,349.95
EBITDA	3,032.21	7,549.80	4,860.50	4,076.75	7,562.93
Depreciation	394.57	2,027.20	2,141.40	907.11	1,961.27
EBIT	2,637.64	5,522.60	2,719.10	3,169.64	5,601.66
Interest	177.62	595.90	450.40	513.87	394.85
Other Income	599.61	1,126.50	1,255.10	326.89	737.13
Exceptional Items	-187.76	-499.30	0.00	-129.75	-105.51
Profit before Tax	2,871.87	5,553.90	3,523.80	2,852.91	5,838.43
Provision for Tax	665.57	1,394.90	764.10	603.22	1,845.38
Profit after Tax	2,206.30	4,159.00	2,759.70	2,249.69	3,993.05

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Shareholder's Funds	13,820.10	27,817.30	38,807.00	17,582.22	39,399.90
Minority Interest	-46.73	-101.90	40.20	-20.87	3.68
Non-Current Liabilities	1,741.34	7,260.60	3,074.90	5,214.33	2,689.12
Current Liabilities	4,782.70	18,023.50	15,430.30	5,884.79	19,667.17
Total Liabilities	20,857.85	50,672.60	56,576.70	27,754.83	58,196.15

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Non-Current Assets	6,708.01	36,142.90	26,891.10	20,096.89	26,331.59
Current Assets	12,210.52	18,433.50	29,732.20	7,956.27	33,958.66
Total Assets	20,857.85	50,672.60	56,576.70	27,754.83	58,196.15
Total Debt*	1,623.50	11,769.50	7,734.10	6,021.78	7,676.20
Net Current Assets	7,427.82	410.00	14,301.90	2,071.48	14,291.49
Contingent Liabilities	1,113.14	989.90	336.14	924.77	1,358.37

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Cash From Operating Activities	1,963.03	2,116.60	5,673.70	3,121.29	5,526.37
Cash Flow from Investing Activities	-1,667.21	-8,296.10	-6,549.30	-196.42	-3,458.61
Cash from Financing Activities	-503.40	5,806.90	829.00	-2,952.69	-1,269.15
Net Cash Inflow / Outflow	-207.58	-372.60	-46.60	-27.82	798.61

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
ROCE (%)	21.28	21.39	13.75	13.24	12.76
ROE (%)	16.76	16.61	7.30	13.86	10.51
ROA (%)	11.44	8.11	4.93	7.79	6.99
EBIT Margin (%)	17.49	18.18	8.22	20.61	15.18
Net Margin (%)	14.07	13.20	8.03	14.32	10.61
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Revenue Growth (%)	13.36	24.02	-3.53	13.53	13.53
EBIT Growth (%)	15.78	-16.48	-58.47	31.59	13.09
Net Profit Growth (%)	-5.47	-16.41	-51.77	27.79	15.82
EPS Growth (%)	0.11	-10.25	-51.50	34.22	19.29
Book Value Growth (%)	15.36	13.19	12.99	13.74	16.04

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Price / Earnings	27.22	26.29	40.57	44.22	25.44
Price / Book Value	4.33	4.29	2.93	5.91	2.61
Dividend Yield (%)	1.02	0.08	0.59	0.04	0.22
EV/EBITDA	20.15	16.41	23.53	26.46	13.22
Market Cap (₹ Cr)	63,401.06	87,643.18	1,04,763.81	82,801.75	75,689.14

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Debt to Equity	0.04	0.15	0.00	0.17	0.02
Short term debt to equity ratio	0.08	0.16	0.16	0.04	0.16
Current Ratio	2.55	1.02	1.93	1.35	1.73
Quick Ratio	1.86	0.64	1.40	0.95	1.06
Interest Coverage	17.17	10.32	8.82	6.55	15.79

	Alkem Laboratories	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma
Debtors to sales (%)	19.75	14.42	30.64	14.17	20.44
Asset Turnover	0.78	0.59	0.59	0.53	0.65
Receivable days	44.04	33.55	103.79	39.93	33.71
Inventory Days	50.59	33.80	79.94	51.78	59.32
Payable days	167.84	149.82	84.78	111.46	148.20
Cash Conversion Cycle	-73.22	-82.46	98.95	-19.75	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.